Lee Hambright
Stock Analyst at Bernstein
(2.85)
# 1,656
Out of 4,847 analysts
22
Total ratings
75%
Success rate
13.38%
Average return
Main Sectors:
Stocks Rated by Lee Hambright
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDT Medtronic | Maintains: Outperform | $96 → $97 | $85.54 | +13.40% | 2 | Nov 20, 2024 | |
| PODD Insulet | Initiates: Outperform | $300 | $323.24 | -7.19% | 1 | Nov 6, 2024 | |
| TNDM Tandem Diabetes Care | Initiates: Outperform | $42 | $20.63 | +103.59% | 1 | Nov 6, 2024 | |
| DXCM DexCom | Maintains: Outperform | $82 → $86 | $86.79 | -0.91% | 2 | Oct 25, 2024 | |
| BSX Boston Scientific | Maintains: Outperform | $92 → $100 | $103.10 | -3.01% | 1 | Oct 24, 2024 | |
| ABT Abbott Laboratories | Maintains: Outperform | $133 → $138 | $133.71 | +3.21% | 2 | Oct 17, 2024 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $350 → $365 | $551.85 | -33.86% | 2 | May 31, 2023 | |
| ZBH Zimmer Biomet Holdings | Maintains: Market Perform | $136 → $152 | $91.85 | +65.49% | 1 | May 3, 2023 | |
| JNJ Johnson & Johnson | Downgrades: Market Perform | $183 | $154.42 | +18.51% | 4 | Mar 16, 2022 | |
| SYK Stryker | Upgrades: Outperform | $288 → $295 | $381.01 | -22.57% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $132 → $135 | $77.72 | +73.70% | 3 | Mar 16, 2022 | |
Medtronic
Nov 20, 2024
Maintains: Outperform
Price Target: $96 → $97
Current: $85.54
Upside: +13.40%
Insulet
Nov 6, 2024
Initiates: Outperform
Price Target: $300
Current: $323.24
Upside: -7.19%
Tandem Diabetes Care
Nov 6, 2024
Initiates: Outperform
Price Target: $42
Current: $20.63
Upside: +103.59%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $82 → $86
Current: $86.79
Upside: -0.91%
Boston Scientific
Oct 24, 2024
Maintains: Outperform
Price Target: $92 → $100
Current: $103.10
Upside: -3.01%
Abbott Laboratories
Oct 17, 2024
Maintains: Outperform
Price Target: $133 → $138
Current: $133.71
Upside: +3.21%
Intuitive Surgical
May 31, 2023
Maintains: Outperform
Price Target: $350 → $365
Current: $551.85
Upside: -33.86%
Zimmer Biomet Holdings
May 3, 2023
Maintains: Market Perform
Price Target: $136 → $152
Current: $91.85
Upside: +65.49%
Johnson & Johnson
Mar 16, 2022
Downgrades: Market Perform
Price Target: $183
Current: $154.42
Upside: +18.51%
Stryker
Mar 16, 2022
Upgrades: Outperform
Price Target: $288 → $295
Current: $381.01
Upside: -22.57%
Mar 16, 2022
Upgrades: Outperform
Price Target: $132 → $135
Current: $77.72
Upside: +73.70%